# Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

> **NCT00345345** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 29 (actual)

## Conditions studied

- T-LGL Lymphoproliferative Disorders

## Interventions

- **BIOLOGICAL:** Alemtuzumab (Campath)

## Key facts

- **NCT ID:** NCT00345345
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-17
- **Primary completion:** 2017-08-01
- **Final completion:** 2020-10-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345345, "Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00345345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*